Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 8, 2025Prospects in Pharmaceutical SciencesOpen Access

Incidence of Adverse and Safety Events in Individuals with Parkinson’s Disease Treated with Catechol-O-Methyltransferase Inhibitor Opicapone as an Add-On to Levodopa Treatment: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

PAPaula AbolaEuropean Business School ParisGJGeorge Jabishvili

Discussion

Loading...

Member takes

Implication

Systematic review examines opicapone's risk of dyskinesia in Parkinson's patients, suggesting careful monitoring.

Key Points

  • Opicapone increased the risk of dyskinesia by 2.47 to 2.75 times compared to placebo, highlighting a key safety concern.
  • Randomized controlled trials and open-label studies reviewed included a total of 2705 participants focusing on adverse event incidence.
  • Analysis included assessment of adverse events using risk ratios, indicating a generally favorable safety profile aside from dyskinesia.
  • Further investigation is recommended to optimize management strategies for dyskinesia and evaluate long-term outcomes.

Cite This Study

Abola et al. (2025) studied this question.

synapsesocial.com/papers/68e5c1c36950a706b22b5bfehttps://doi.org/10.56782/pps.563
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson’s disease: pooled analysis of patient level data from two randomized open-label studies2024 · 10 citations
  2. 2Long-term safety and efficacy of opicapone in Japanese Parkinson’s patients with motor fluctuations2021 · 12 citations
  3. 3Levodopa‐induced dyskinesias2007 · 466 citations
  4. 4RoB 2: a revised tool for assessing risk of bias in randomised trials2019 · 33,583 citations
  5. 5GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings2021 · 324 citations